Ratings AFT Pharmaceuticals Limited

Equities

AFT

NZAFTE0001S4

End-of-day quote New Zealand S.E. 23:00:00 20/06/2024 BST 5-day change 1st Jan Change
2.85 NZD -6.25% Intraday chart for AFT Pharmaceuticals Limited -9.81% -18.57%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-18.57% 183M -
+51.63% 796B
C+
+41.51% 628B
B
-5.10% 358B
C+
+19.90% 331B
B-
+9.95% 301B
C+
+17.66% 244B
B+
+3.39% 228B
A+
+10.75% 214B
B-
+6.99% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AFT Stock
  4. Ratings AFT Pharmaceuticals Limited